UBS Group’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-9,830
| Closed | -$6K | – | 10336 |
|
|
2022
Q2 | $6K | Buy |
9,830
+8,248
| +521% | +$5.03K | ﹤0.01% | 7769 |
|
|
2022
Q1 | $2K | Sell |
1,582
-3,018
| -66% | -$3.82K | ﹤0.01% | 8731 |
|
|
2021
Q4 | $12K | Buy |
4,600
+3,600
| +360% | +$9.39K | ﹤0.01% | 7507 |
|
|
2021
Q3 | $3K | Sell |
1,000
-3,087
| -76% | -$9.26K | ﹤0.01% | 7742 |
|
|
2021
Q2 | $15K | Sell |
4,087
-4,063
| -50% | -$14.9K | ﹤0.01% | 6574 |
|
|
2021
Q1 | $28K | Buy |
8,150
+6,842
| +523% | +$23.5K | ﹤0.01% | 6066 |
|
|
2020
Q4 | $4K | Buy |
+1,308
| New | +$4K | ﹤0.01% | 6919 |
|
|
2020
Q3 | – | Sell |
-8,121
| Closed | -$37K | – | 7565 |
|
|
2020
Q2 | $37K | Sell |
8,121
-1,742
| -18% | -$7.94K | ﹤0.01% | 5284 |
|
|
2020
Q1 | $33K | Sell |
9,863
-8,196
| -45% | -$27.4K | ﹤0.01% | 5257 |
|
|
2019
Q4 | $110K | Buy |
18,059
+5,139
| +40% | +$31.3K | ﹤0.01% | 4925 |
|
|
2019
Q3 | $54K | Buy |
12,920
+9,506
| +278% | +$39.7K | ﹤0.01% | 5224 |
|
|
2019
Q2 | $45K | Buy |
3,414
+1,669
| +96% | +$22K | ﹤0.01% | 5156 |
|
|
2019
Q1 | $17K | Buy |
+1,745
| New | +$17K | ﹤0.01% | 5616 |
|